{
  "identity": {
    "bacteriumName": "Citrobacter koseri",
    "aliases": [
      "Citrobacter diversus"
    ],
    "lastUpdated": "2025-01-17",
    "clsiCategory": "Enterobacterales (excluding Salmonella/Shigella)",
    "classification": {
      "gramStain": "Gram negative",
      "morphology": "Bacilli",
      "respiration": "Facultative anaerobe",
      "notes": [
        "Grows aerobically and anaerobically."
      ]
    },
    "strainDetails": [],
    "biochemicalTests": "Gram-negative rod, motile, lactose fermenter, H2S –, indole +, citrate +, lysine decarboxylase +, ornithine decarboxylase +."
  },
  "clinicalProfile": {
    "summary": "Citrobacter species cause a variety of infections ranging from uncomplicated urinary tract infections to life-threatening infections of the abdomen, skin and soft tissue, lung, CNS and other sites in both normal and immuno-compromised hosts.",
    "pathophysiologyPearls": [
      "Unlike Citrobacter freundii, Citrobacter koseri does not have repressed chromosomal ampC genes. Hence it is safe to use ceftriaxone if the isolate is both speciated as C. koseri and is susceptible in vitro."
    ],
    "keySignsAndSymptoms": [],
    "clinicalSyndromes": [
      {
        "syndromeName": "Urinary Tract Infections (UTI)",
        "description": "Can range from uncomplicated cystitis to complicated infections."
      },
      {
        "syndromeName": "Intra-abdominal Infections",
        "description": "Infections within the abdominal cavity."
      },
      {
        "syndromeName": "Skin and Soft Tissue Infections",
        "description": "Infections involving the skin and underlying structures."
      },
      {
        "syndromeName": "Pneumonia",
        "description": "Infection of the lungs."
      },
      {
        "syndromeName": "Central Nervous System (CNS) Infections",
        "description": "Life-threatening infections of the central nervous system, particularly in neonates."
      }
    ],
    "stagesOfIllness": [],
    "highRiskPopulations": [
      "Immuno-compromised hosts",
      "Neonates"
    ],
    "transmissionVectors": [],
    "prognosisNotes": []
  },
  "resistanceProfile": {
    "groupIntrinsicResistance": [],
    "intrinsicResistance": [
      {
        "drugOrClass": "Multiple Beta-Lactams",
        "notes": "Citrobacter koseri predicably encodes an inducible ampC chromosomal gene. It is de-repressed during clinical therapy with Ceftriaxone, Cefotaxime, Ceftazidime, Aztreonam, or Piperacillin-tazobactam, leading to clinical failure."
      }
    ],
    "majorMechanisms": [
      {
        "mechanismName": "Extended-Spectrum Beta-Lactamases (ESBLs)",
        "mechanismType": "Enzymatic Inactivation",
        "description": "Citrobacter strains can produce ESBLs, which destroy the antibacterial activity of most extended-spectrum cephalosporins, penicillins, and aztreonam, though Cefepime may be an exception."
      },
      {
        "mechanismName": "Serine Carbapenemases (KPC)",
        "mechanismType": "Enzymatic Inactivation",
        "description": "Resistance to all carbapenems, cephalosporins, penicillins, fluoroquinolones, and aminoglycosides can be consistent with the production of Klebsiella-producing serine based carbapenemases (KPCs)."
      },
      {
        "mechanismName": "Metallo-Carbapenemase (MBL)",
        "mechanismType": "Enzymatic Inactivation",
        "description": "Resistance to meropenem-vaborbactam, ceftazidime-avibactam, all carbapenems, and other beta-lactams is consistent with production of metallo-carbapenemase."
      }
    ],
    "clinicalAlerts": [
      {
        "alertTitle": "Absence of Inducible AmpC",
        "details": "A critical distinction is that C. koseri does not house the inducible ampC gene, unlike C. freundii. Therefore, third-generation cephalosporins (e.g., ceftriaxone) are safe and effective if the isolate is confirmed as C. koseri and tests susceptible in vitro. If the lab report only specifies 'Citrobacter species,' cephalosporins should be avoided regardless of susceptibility results due to the risk of AmpC induction with C. freundii."
      },
      {
        "alertTitle": "Co-resistance",
        "details": "Strains often exhibit concomitant resistance to fluoroquinolones, aminoglycosides, and TMP/SMX."
      }
    ]
  },
  "treatment": {
    "generalNotes": [
      "Choice of empiric regimen depends on local resistance patterns, the fragility of the patient, and the severity of the infection.",
      "Specific therapy is directed by the results of in vitro susceptibility testing.",
      "For uncomplicated cystitis, see Cystitis, adult female guidelines."
    ],
    "drugsToAvoid": [],
    "adjunctiveTherapies": [],
    "regimens": [
      {
        "context": {
          "type": "Empiric",
          "condition": "Citrobacter koseri identified, susceptibility pending",
          "patientPopulation": [
            "Local rate of ESBL <10-15%"
          ],
          "isolateSource": null
        },
        "recommendations": [
          {
            "preference": "Primary",
            "strategy": "Concurrent",
            "steps": [
              {
                "step": 1,
                "duration": "Variable",
                "drugs": [
                  {
                    "drugName": "Piperacillin-tazobactam",
                    "dose": "4.5 gm",
                    "route": "IV",
                    "frequency": "q6h",
                    "comments": "Infused over 4 hr."
                  },
                  {
                    "drugName": "Ceftriaxone",
                    "dose": "2 gm",
                    "route": "IV",
                    "frequency": "daily",
                    "comments": "Safe to use as C. koseri does not have inducible ampC genes."
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "context": {
          "type": "Empiric",
          "condition": "Citrobacter koseri identified, susceptibility pending",
          "patientPopulation": [
            "Local rate of ESBL >15%"
          ],
          "isolateSource": null
        },
        "recommendations": [
          {
            "preference": "Primary",
            "strategy": "Concurrent",
            "steps": [
              {
                "step": 1,
                "duration": "Variable",
                "drugs": [
                  {
                    "drugName": "Meropenem",
                    "dose": "1-2 gm",
                    "route": "IV",
                    "frequency": "q8h",
                    "comments": ""
                  },
                  {
                    "drugName": "Ertapenem",
                    "dose": "1 gm",
                    "route": "IV",
                    "frequency": "q24h",
                    "comments": ""
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "context": {
          "type": "Directed",
          "condition": "No in vitro resistance detected",
          "patientPopulation": [],
          "isolateSource": "Systemic (IV therapy)"
        },
        "recommendations": [
          {
            "preference": "Primary",
            "strategy": "Concurrent",
            "steps": [
              {
                "step": 1,
                "duration": "Variable",
                "drugs": [
                  {
                    "drugName": "Piperacillin-tazobactam",
                    "dose": "4.5 gm (infused over 4 hr)",
                    "route": "IV",
                    "frequency": "q6h",
                    "comments": ""
                  },
                  {
                    "drugName": "Ciprofloxacin",
                    "dose": "400 mg",
                    "route": "IV",
                    "frequency": "q12h",
                    "comments": ""
                  },
                  {
                    "drugName": "Levofloxacin",
                    "dose": "750 mg",
                    "route": "IV",
                    "frequency": "once daily",
                    "comments": ""
                  },
                  {
                    "drugName": "Ceftriaxone",
                    "dose": "2 gms",
                    "route": "IV",
                    "frequency": "daily",
                    "comments": ""
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "context": {
          "type": "Directed",
          "condition": "No in vitro resistance detected",
          "patientPopulation": [],
          "isolateSource": "Urine (PO therapy)"
        },
        "recommendations": [
          {
            "preference": "Primary",
            "strategy": "Concurrent",
            "steps": [
              {
                "step": 1,
                "duration": "Variable",
                "drugs": [
                  {
                    "drugName": "Cefixime",
                    "dose": "Varies",
                    "route": "PO",
                    "frequency": "Varies",
                    "comments": ""
                  },
                  {
                    "drugName": "Cefdinir",
                    "dose": "Varies",
                    "route": "PO",
                    "frequency": "Varies",
                    "comments": ""
                  },
                  {
                    "drugName": "Fosfomycin",
                    "dose": "3 gm po x 1 dose",
                    "route": "PO",
                    "frequency": "Single dose",
                    "comments": "For uncomplicated cystitis. Note: CLSI breakpoints are only validated for E. coli."
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "context": {
          "type": "Directed",
          "condition": "ESBL Producer",
          "patientPopulation": [
            "Resistance to aztreonam, ceftriaxone, cefotaxime"
          ],
          "isolateSource": null
        },
        "recommendations": [
          {
            "preference": "Primary",
            "strategy": "Concurrent",
            "steps": [
              {
                "step": 1,
                "duration": "Variable",
                "drugs": [
                  {
                    "drugName": "Meropenem",
                    "dose": "1-2 gm",
                    "route": "IV",
                    "frequency": "q8h",
                    "comments": ""
                  },
                  {
                    "drugName": "Ertapenem",
                    "dose": "1 gm",
                    "route": "IV",
                    "frequency": "q24h",
                    "comments": ""
                  }
                ]
              }
            ]
          },
          {
            "preference": "Alternative",
            "strategy": "Concurrent",
            "steps": [
              {
                "step": 1,
                "duration": "Variable",
                "drugs": [
                  {
                    "drugName": "Ceftolozane-tazobactam",
                    "dose": "1.5 gm",
                    "route": "IV",
                    "frequency": "q8h",
                    "comments": "Infuse over 3h."
                  },
                  {
                    "drugName": "Temocillin",
                    "dose": "2 gm",
                    "route": "IV",
                    "frequency": "q12h",
                    "comments": "Availability is limited."
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "context": {
          "type": "Directed",
          "condition": "Serine Carbapenemase (KPC) Producer",
          "patientPopulation": [
            "Resistant to carbapenems but susceptible to newer beta-lactamase inhibitor combinations"
          ],
          "isolateSource": null
        },
        "recommendations": [
          {
            "preference": "Primary",
            "strategy": "Concurrent",
            "steps": [
              {
                "step": 1,
                "duration": "Variable",
                "drugs": [
                  {
                    "drugName": "Meropenem-vaborbactam",
                    "dose": "4 gm",
                    "route": "IV",
                    "frequency": "q8h",
                    "comments": "Infused over 3h."
                  },
                  {
                    "drugName": "Ceftazidime-avibactam",
                    "dose": "2.5 gm",
                    "route": "IV",
                    "frequency": "q8h",
                    "comments": "Infused over 2 hrs."
                  },
                  {
                    "drugName": "Imipenem-cilastatin-relebactam",
                    "dose": "1.25 gm",
                    "route": "IV",
                    "frequency": "q6h",
                    "comments": "Infused over 30 min (for CrCl > 90 mL/min)."
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "context": {
          "type": "Directed",
          "condition": "Metallo-Carbapenemase (MBL) Producer",
          "patientPopulation": [
            "Resistant to meropenem-vaborbactam, ceftazidime-avibactam, and all carbapenems"
          ],
          "isolateSource": null
        },
        "recommendations": [
          {
            "preference": "Primary",
            "strategy": "Concurrent",
            "steps": [
              {
                "step": 1,
                "duration": "Variable",
                "drugs": [
                  {
                    "drugName": "Ceftazidime-avibactam",
                    "dose": "2.5 gm",
                    "route": "IV",
                    "frequency": "q8h",
                    "comments": "Infused over 3 hrs. Must be given with Aztreonam."
                  },
                  {
                    "drugName": "Aztreonam",
                    "dose": "2 gm",
                    "route": "IV",
                    "frequency": "q8h",
                    "comments": "Infused over 3h. Must be given with Ceftazidime-avibactam."
                  }
                ]
              }
            ]
          },
          {
            "preference": "Alternative",
            "strategy": "Concurrent",
            "steps": [
              {
                "step": 1,
                "duration": "Variable",
                "drugs": [
                  {
                    "drugName": "Cefiderocol",
                    "dose": "2 gm",
                    "route": "IV",
                    "frequency": "q8h",
                    "comments": "Infuse over 3h."
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "context": {
          "type": "Directed",
          "condition": "Pan-resistant infection",
          "patientPopulation": [
            "Resistant to all normally tested classes of FDA approved anti-infectives"
          ],
          "isolateSource": null
        },
        "recommendations": [
          {
            "preference": "Primary",
            "strategy": "Concurrent",
            "steps": [
              {
                "step": 1,
                "duration": "Variable",
                "drugs": [
                  {
                    "drugName": "Fosfomycin",
                    "dose": "Varies",
                    "route": "IV",
                    "frequency": "Varies",
                    "comments": "IV formulation availability is limited."
                  },
                  {
                    "drugName": "Cefiderocol",
                    "dose": "2 gm",
                    "route": "IV",
                    "frequency": "q8h",
                    "comments": "Infused over 3h."
                  }
                ]
              }
            ]
          }
        ]
      }
    ]
  },
  "laboratoryProfile": {
    "clsiCategory": "Enterobacterales (excluding Salmonella/Shigella)",
    "testingIndications": [],
    "methodologyNotes": [
      "For Citrobacter freundii complex, Enterobacter cloacae complex, Klebsiella aerogenes, Morganella morganii, Providencia spp., and Serratia marcescens, isolates that initially test susceptible to third-generation cephalosporins may develop resistance during therapy due to derepression of inducible AmpC β-lactamase. While C. koseri is not typically listed in this high-risk group, speciation is crucial to differentiate it from C. freundii."
    ],
    "recommendedPanel": [],
    "specialTests": [],
    "reportingRules": [
      {
        "ruleType": "Surrogate",
        "drug": "Cefazolin",
        "condition": "Uncomplicated UTI",
        "details": "For isolates from uncomplicated UTIs, cefazolin susceptibility can be used as a surrogate marker to predict susceptibility to oral cephalosporins like cephalexin, cefaclor, cefdinir, cefpodoxime, cefprozil, cefuroxime axetil, and loracarbef. This rule specifically applies to E. coli, K. pneumoniae, and P. mirabilis."
      },
      {
        "ruleType": "Conditional",
        "drug": "Fosfomycin",
        "condition": "Isolate is not E. coli from a urinary tract source.",
        "details": "Fosfomycin breakpoints (MIC and disk) are for E. coli from urinary tract isolates only and should not be used for other genera, including Citrobacter."
      },
      {
        "ruleType": "Conditional",
        "drug": "Colistin/Polymyxin B",
        "condition": "Any isolate",
        "details": "Disk diffusion and gradient diffusion methods are unreliable and should not be performed. Broth microdilution is the recommended method."
      }
    ],
    "antimicrobialBreakpoints": [
      {
        "tier": 1,
        "tierDescription": "Appropriate for routine, primary testing and reporting.",
        "agents": [
          {
            "agentName": "Ampicillin",
            "breakpointSets": [
              {
                "condition": "Standard",
                "diskDiffusion": {
                  "diskContent": "10 µg",
                  "s_breakpoint": "≥ 17 mm",
                  "i_breakpoint": "14–16 mm",
                  "r_breakpoint": "≤ 13 mm"
                },
                "mic": {
                  "s_breakpoint": "≤ 8 µg/mL",
                  "i_breakpoint": "16 µg/mL",
                  "r_breakpoint": "≥ 32 µg/mL"
                },
                "comments": [
                  "Results can predict amoxicillin results."
                ]
              }
            ]
          },
          {
            "agentName": "Amoxicillin-clavulanate",
            "breakpointSets": [
              {
                "condition": "Uncomplicated UTI only",
                "diskDiffusion": {
                  "diskContent": "20/10 µg",
                  "s_breakpoint": "≥ 18 mm",
                  "i_breakpoint": "—",
                  "r_breakpoint": "≤ 17 mm"
                },
                "mic": {
                  "s_breakpoint": "≤ 8/4 µg/mL",
                  "i_breakpoint": "16/4 µg/mL",
                  "r_breakpoint": "≥ 32/4 µg/mL"
                },
                "comments": [
                  "Breakpoints apply for therapy of uncomplicated UTIs or for completion of therapy for systemic infection."
                ]
              }
            ]
          },
          {
            "agentName": "Piperacillin-tazobactam",
            "breakpointSets": [
              {
                "condition": "Standard",
                "diskDiffusion": {
                  "diskContent": "100/10 µg",
                  "s_breakpoint": "≥ 25 mm",
                  "i_breakpoint": "21–24 mm",
                  "r_breakpoint": "≤ 20 mm"
                },
                "mic": {
                  "s_breakpoint": "≤ 8/4 µg/mL",
                  "i_breakpoint": "16/4 µg/mL",
                  "r_breakpoint": "≥ 32/4 µg/mL"
                },
                "comments": []
              }
            ]
          },
          {
            "agentName": "Ciprofloxacin",
            "breakpointSets": [
              {
                "condition": "Standard",
                "diskDiffusion": {
                  "diskContent": "5 µg",
                  "s_breakpoint": "≥ 26 mm",
                  "i_breakpoint": "22–25 mm",
                  "r_breakpoint": "≤ 21 mm"
                },
                "mic": {
                  "s_breakpoint": "≤ 0.25 µg/mL",
                  "i_breakpoint": "0.5 µg/mL",
                  "r_breakpoint": "≥ 1 µg/mL"
                },
                "comments": []
              }
            ]
          },
          {
            "agentName": "Levofloxacin",
            "breakpointSets": [
              {
                "condition": "Standard",
                "diskDiffusion": {
                  "diskContent": "5 µg",
                  "s_breakpoint": "≥ 21 mm",
                  "i_breakpoint": "17–20 mm",
                  "r_breakpoint": "≤ 16 mm"
                },
                "mic": {
                  "s_breakpoint": "≤ 0.5 µg/mL",
                  "i_breakpoint": "1 µg/mL",
                  "r_breakpoint": "≥ 2 µg/mL"
                },
                "comments": []
              }
            ]
          },
          {
            "agentName": "Trimethoprim-sulfamethoxazole",
            "breakpointSets": [
              {
                "condition": "Standard",
                "diskDiffusion": {
                  "diskContent": "1.25/23.75 µg",
                  "s_breakpoint": "≥ 16 mm",
                  "i_breakpoint": "11–15 mm",
                  "r_breakpoint": "≤ 10 mm"
                },
                "mic": {
                  "s_breakpoint": "≤ 2/38 µg/mL",
                  "i_breakpoint": "—",
                  "r_breakpoint": "≥ 4/76 µg/mL"
                },
                "comments": []
              }
            ]
          }
        ]
      },
      {
        "tier": 2,
        "tierDescription": "Appropriate for routine, primary testing, may be reported following cascade reporting rules.",
        "agents": [
          {
            "agentName": "Cefepime",
            "breakpointSets": [
              {
                "condition": "Standard",
                "diskDiffusion": {
                  "diskContent": "30 µg",
                  "s_breakpoint": "≥ 25 mm",
                  "i_breakpoint": "19–24 mm",
                  "r_breakpoint": "≤ 18 mm"
                },
                "mic": {
                  "s_breakpoint": "≤ 4 µg/mL",
                  "i_breakpoint": "8 µg/mL",
                  "r_breakpoint": "≥ 16 µg/mL"
                },
                "comments": [
                  "Cefepime S/SDD results should be suppressed or reported as resistant for isolates demonstrating carbapenemase production."
                ]
              }
            ]
          },
          {
            "agentName": "Ertapenem",
            "breakpointSets": [
              {
                "condition": "Standard",
                "diskDiffusion": {
                  "diskContent": "10 µg",
                  "s_breakpoint": "≥ 22 mm",
                  "i_breakpoint": "19–21 mm",
                  "r_breakpoint": "≤ 18 mm"
                },
                "mic": {
                  "s_breakpoint": "≤ 0.5 µg/mL",
                  "i_breakpoint": "1 µg/mL",
                  "r_breakpoint": "≥ 2 µg/mL"
                },
                "comments": []
              }
            ]
          },
          {
            "agentName": "Meropenem",
            "breakpointSets": [
              {
                "condition": "Standard",
                "diskDiffusion": {
                  "diskContent": "10 µg",
                  "s_breakpoint": "≥ 23 mm",
                  "i_breakpoint": "20–22 mm",
                  "r_breakpoint": "≤ 19 mm"
                },
                "mic": {
                  "s_breakpoint": "≤ 1 µg/mL",
                  "i_breakpoint": "2 µg/mL",
                  "r_breakpoint": "≥ 4 µg/mL"
                },
                "comments": []
              }
            ]
          }
        ]
      },
      {
        "tier": 3,
        "tierDescription": "Appropriate for high-risk MDRO patients, subject to cascade reporting.",
        "agents": [
          {
            "agentName": "Ceftazidime-avibactam",
            "breakpointSets": [
              {
                "condition": "Standard",
                "diskDiffusion": {
                  "diskContent": "30/20 µg",
                  "s_breakpoint": "≥ 21 mm",
                  "i_breakpoint": "—",
                  "r_breakpoint": "≤ 20 mm"
                },
                "mic": {
                  "s_breakpoint": "≤ 8/4 µg/mL",
                  "i_breakpoint": "—",
                  "r_breakpoint": "≥ 16/4 µg/mL"
                },
                "comments": [
                  "Confirmatory MIC testing is indicated for isolates with disk diffusion zones of 20–22 mm."
                ]
              }
            ]
          },
          {
            "agentName": "Meropenem-vaborbactam",
            "breakpointSets": [
              {
                "condition": "Standard",
                "diskDiffusion": {
                  "diskContent": "20/10 µg",
                  "s_breakpoint": "≥ 18 mm",
                  "i_breakpoint": "15–17 mm",
                  "r_breakpoint": "≤ 14 mm"
                },
                "mic": {
                  "s_breakpoint": "≤ 4/8 µg/mL",
                  "i_breakpoint": "8/8 µg/mL",
                  "r_breakpoint": "≥ 16/8 µg/mL"
                },
                "comments": [
                  "If an OXA-48-like gene or enzyme is detected, suppress or report as resistant."
                ]
              }
            ]
          },
          {
            "agentName": "Imipenem-relebactam",
            "breakpointSets": [
              {
                "condition": "Standard",
                "diskDiffusion": {
                  "diskContent": "10/25 µg",
                  "s_breakpoint": "≥ 25 mm",
                  "i_breakpoint": "21–24 mm",
                  "r_breakpoint": "≤ 20 mm"
                },
                "mic": {
                  "s_breakpoint": "≤ 1/4 µg/mL",
                  "i_breakpoint": "2/4 µg/mL",
                  "r_breakpoint": "≥ 4/4 µg/mL"
                },
                "comments": [
                  "Breakpoints do not apply to the family Morganellaceae (Morganella, Proteus, and Providencia)."
                ]
              }
            ]
          }
        ]
      },
      {
        "tier": 4,
        "tierDescription": "May warrant testing and reporting by clinician request.",
        "agents": [
          {
            "agentName": "Ceftriaxone",
            "breakpointSets": [
              {
                "condition": "Standard",
                "diskDiffusion": {
                  "diskContent": "30 µg",
                  "s_breakpoint": "≥ 26 mm",
                  "i_breakpoint": "20–22 mm",
                  "r_breakpoint": "≤ 19 mm"
                },
                "mic": {
                  "s_breakpoint": "≤ 1 µg/mL",
                  "i_breakpoint": "2 µg/mL",
                  "r_breakpoint": "≥ 4 µg/mL"
                },
                "comments": []
              }
            ]
          },
          {
            "agentName": "Aztreonam",
            "breakpointSets": [
              {
                "condition": "Standard",
                "diskDiffusion": {
                  "diskContent": "30 µg",
                  "s_breakpoint": "≥ 21 mm",
                  "i_breakpoint": "18–20 mm",
                  "r_breakpoint": "≤ 17 mm"
                },
                "mic": {
                  "s_breakpoint": "≤ 4 µg/mL",
                  "i_breakpoint": "8 µg/mL",
                  "r_breakpoint": "≥ 16 µg/mL"
                },
                "comments": []
              }
            ]
          }
        ]
      },
      {
        "tier": 0,
        "tierDescription": "Urine Only Tier",
        "agents": [
          {
            "agentName": "Nitrofurantoin",
            "breakpointSets": [
              {
                "condition": "Urine Only",
                "diskDiffusion": {
                  "diskContent": "300 µg",
                  "s_breakpoint": "≥ 17 mm",
                  "i_breakpoint": "15–16 mm",
                  "r_breakpoint": "≤ 14 mm"
                },
                "mic": {
                  "s_breakpoint": "≤ 32 µg/mL",
                  "i_breakpoint": "64 µg/mL",
                  "r_breakpoint": "≥ 128 µg/mL"
                },
                "comments": []
              }
            ]
          },
          {
            "agentName": "Cefazolin",
            "breakpointSets": [
              {
                "condition": "Uncomplicated UTI only",
                "diskDiffusion": {
                  "diskContent": "30 µg",
                  "s_breakpoint": "≥ 15 mm",
                  "i_breakpoint": "—",
                  "r_breakpoint": "≤ 14 mm"
                },
                "mic": {
                  "s_breakpoint": "≤ 16 µg/mL",
                  "i_breakpoint": "—",
                  "r_breakpoint": "≥ 32 µg/mL"
                },
                "comments": [
                  "Serves as a surrogate for oral cephalosporins for E. coli, K. pneumoniae, and P. mirabilis."
                ]
              }
            ]
          },
          {
            "agentName": "Fosfomycin",
            "breakpointSets": [
              {
                "condition": "Urine Only",
                "diskDiffusion": {
                  "diskContent": "200 µg",
                  "s_breakpoint": "≥ 16 mm",
                  "i_breakpoint": "13–15 mm",
                  "r_breakpoint": "≤ 12 mm"
                },
                "mic": {
                  "s_breakpoint": "≤ 64 µg/mL",
                  "i_breakpoint": "128 µg/mL",
                  "r_breakpoint": "≥ 256 µg/mL"
                },
                "comments": [
                  "Applies only to E. coli urinary tract isolates and should not be extrapolated to other Enterobacterales species. The 200 µg fosfomycin disk contains 50 µg glucose-6-phosphate."
                ]
              }
            ]
          }
        ]
      }
    ]
  },
  "additionalInformation": {
    "diagnosticNotes": {
      "summary": "",
      "biosafetyWarning": "",
      "methods": []
    },
    "preventionAndScreening": [],
    "treatmentLifecycle": [],
    "antimicrobialStewardship": [
      "Reserve carbapenems for Citrobacter infections that in addition need anaerobic coverage or for treatment of ESBL producing strains.",
      "Reserve Meropenem-vaborbactam, Imipenem-cilastatin-relebactam, and Ceftazidime-avibactam for patients with documented KPC infections."
    ],
    "drugSpecificPearls": [
      {
        "drugName": "Cephalosporins",
        "pearl": "C. koseri does not house the ampC gene, making third-generation cephalosporins safe and effective if the isolate is susceptible in vitro. This is a key difference from C. freundii, where cephalosporins should be avoided due to risk of inducible resistance."
      },
      {
        "drugName": "Cefiderocol",
        "pearl": "FDA-approved for patients with complicated UTI with limited or no alternative treatment options. In a trial comparing Cefiderocol to the Best Available Therapy (BAT) for serious infections, 28-day mortality was 24.8% for cefiderocol versus 18.4% for BAT (not statistically significant)."
      },
      {
        "drugName": "Plazomicin",
        "pearl": "Approved for complicated UTI. There is limited observational experience using it in combination with Tigecycline or Meropenem for MDR bacteremia or ventilator-associated pneumonia."
      }
    ],
    "guidelineReferences": [
      {
        "source": "IDSA",
        "citation": "IDSA 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections.",
        "summaryOrNote": "Provides a framework for managing infections caused by resistant gram-negative organisms, including Citrobacter spp."
      },
      {
        "source": "Antimicrobial Agents and Chemotherapy",
        "citation": "Antimicrob Agents Chemother 2017 Mar 24; 61(4). pii:e02243-16.",
        "summaryOrNote": "Discusses the rationale for combining Ceftazidime-avibactam with Aztreonam for treating MBL-producing bacteria."
      },
      {
        "source": "New England Journal of Medicine",
        "citation": "N Engl J Med 2019; 380: 791.",
        "summaryOrNote": "Presents observational data on Plazomicin for MDR infections."
      }
    ]
  }
}
